Advice
in the absence of a submission from the holder of the marketing authorisation
catumaxomab (Removab®) is not recommended for use within NHS Scotland.
Indication under review: Intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice89KB (PDF)
Medicine details
- Medicine name:
- catumaxomab (Removab)
- SMC ID:
- 788/12
- Indication:
- Intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible.
- Pharmaceutical company
- Fresenius Medical Care (UK) Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 09 April 2012